Lead Product(s) : Cantharidin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Verrica Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Torii Files NDA in Japan for TO-208 in Molluscum Contagiosum
Details : TO-208 previously known as VP-102 is a single-use drug device combination product containing (cantharidin) topical solution. It is being evaluated for the treatment of Molluscum Contagiosum.
Product Name : TO-208
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 06, 2024
Lead Product(s) : Cantharidin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Verrica Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : L-praziquantel
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children
Details : Arpraziquantel (L-praziquantel) orodispersible tablet is a CYP11B1 inhibitor which is being evaluated for the treatment of Schistosomiasis in preschool-aged children.
Product Name : Arpraziquantel
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 18, 2023
Lead Product(s) : L-praziquantel
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DS-5670
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DS-5670 is an mRNA vaccine against COVID-19 designed to produce antibodies against the receptor binding domain (RBD) of the spike protein of the novel coronavirus.
Product Name : DS-5670
Product Type : Vaccine
Upfront Cash : Inapplicable
July 09, 2023
Lead Product(s) : DS-5670
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DS-5670
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DS-5670 is an mRNA vaccine against COVID-19 designed to produce antibodies against the receptor binding domain (RBD) of the spike protein of the novel coronavirus.
Product Name : DS-5670
Product Type : Vaccine
Upfront Cash : Inapplicable
July 09, 2023
Lead Product(s) : DS-5670
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : mRNA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Daiichi Sankyo Initiates Phase 3 Clinical Trial of Mutant Strain COVID-19 Vaccine (DS-5670) in Japan
Details : DS-5670 is an mRNA vaccine against COVID-19 using a novel nucleic acid delivery technology, designed to produce antibodies against the receptor binding domain of the spike protein of the novel coronavirus, and thus expected to have safety and prevention ...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 19, 2023
Lead Product(s) : mRNA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : S-268019
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : S-268019 is a recombinant protein-based preventive vaccine, for use in priming and booster (3rd) doses, against COVID-19, caused by the novel coronavirus (SARS-CoV-2) infection.
Product Name : S-268019
Product Type : Vaccine
Upfront Cash : Inapplicable
January 17, 2023
Lead Product(s) : S-268019
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : mRNA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DS-5670 is an mRNA vaccine against COVID-19 using a novel nucleic acid delivery technology, designed to produce antibodies against the receptor binding domain of the spike protein of the novel coronavirus, and thus expected to have safety and prevention ...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
January 13, 2023
Lead Product(s) : mRNA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 9vHPV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 22, 2022
Lead Product(s) : 9vHPV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : mRNA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DS-5670 is mRNA vaccine against COVID-19 using novel nucleic acid delivery technology designed to produce antibodies against the receptor binding domain of spike protein of novel coronavirus, and thus expected to have desirable prevention against COVID-1...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 15, 2022
Lead Product(s) : mRNA COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 9vHPV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Takeda’s tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
October 14, 2022
Lead Product(s) : 9vHPV Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable